Cargando…
Towards Next Generation Biomarkers in Natural Killer/T-Cell Lymphoma
Natural killer/T-cell lymphoma (NKTCL) is an Epstein–Barr virus-associated non-Hodgkin lymphoma linked to an aggressive clinical course and poor prognosis. Despite an improvement in survival outcomes with the incorporation of novel agents including immune checkpoint inhibitors in the treatment of NK...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8398475/ https://www.ncbi.nlm.nih.gov/pubmed/34440582 http://dx.doi.org/10.3390/life11080838 |
_version_ | 1783744849057415168 |
---|---|
author | Chan, Jason Yongsheng Lim, Jing Quan Ong, Choon Kiat |
author_facet | Chan, Jason Yongsheng Lim, Jing Quan Ong, Choon Kiat |
author_sort | Chan, Jason Yongsheng |
collection | PubMed |
description | Natural killer/T-cell lymphoma (NKTCL) is an Epstein–Barr virus-associated non-Hodgkin lymphoma linked to an aggressive clinical course and poor prognosis. Despite an improvement in survival outcomes with the incorporation of novel agents including immune checkpoint inhibitors in the treatment of NKTCL, a significant proportion of patients still relapse or remain refractory to treatment. Several clinical prognostic models have been developed for NKTCL patients treated in the modern era, though the optimal approach to risk stratification remains to be determined. Novel molecular biomarkers derived from multi-omic profiling have recently been developed, with the potential to improve diagnosis, prognostication and treatment of this disease. Notably, a number of potential biomarkers have emerged from a better understanding of the tumor immune microenvironment and inflammatory responses. This includes a recently described 3′UTR structural variant in the PD-L1 gene, which confers susceptibility to checkpoint immunotherapy. In this review, we summarize the biomarker landscape of NKTCL and highlight emerging biomarkers with the potential for clinical implementation. |
format | Online Article Text |
id | pubmed-8398475 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83984752021-08-29 Towards Next Generation Biomarkers in Natural Killer/T-Cell Lymphoma Chan, Jason Yongsheng Lim, Jing Quan Ong, Choon Kiat Life (Basel) Review Natural killer/T-cell lymphoma (NKTCL) is an Epstein–Barr virus-associated non-Hodgkin lymphoma linked to an aggressive clinical course and poor prognosis. Despite an improvement in survival outcomes with the incorporation of novel agents including immune checkpoint inhibitors in the treatment of NKTCL, a significant proportion of patients still relapse or remain refractory to treatment. Several clinical prognostic models have been developed for NKTCL patients treated in the modern era, though the optimal approach to risk stratification remains to be determined. Novel molecular biomarkers derived from multi-omic profiling have recently been developed, with the potential to improve diagnosis, prognostication and treatment of this disease. Notably, a number of potential biomarkers have emerged from a better understanding of the tumor immune microenvironment and inflammatory responses. This includes a recently described 3′UTR structural variant in the PD-L1 gene, which confers susceptibility to checkpoint immunotherapy. In this review, we summarize the biomarker landscape of NKTCL and highlight emerging biomarkers with the potential for clinical implementation. MDPI 2021-08-16 /pmc/articles/PMC8398475/ /pubmed/34440582 http://dx.doi.org/10.3390/life11080838 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Chan, Jason Yongsheng Lim, Jing Quan Ong, Choon Kiat Towards Next Generation Biomarkers in Natural Killer/T-Cell Lymphoma |
title | Towards Next Generation Biomarkers in Natural Killer/T-Cell Lymphoma |
title_full | Towards Next Generation Biomarkers in Natural Killer/T-Cell Lymphoma |
title_fullStr | Towards Next Generation Biomarkers in Natural Killer/T-Cell Lymphoma |
title_full_unstemmed | Towards Next Generation Biomarkers in Natural Killer/T-Cell Lymphoma |
title_short | Towards Next Generation Biomarkers in Natural Killer/T-Cell Lymphoma |
title_sort | towards next generation biomarkers in natural killer/t-cell lymphoma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8398475/ https://www.ncbi.nlm.nih.gov/pubmed/34440582 http://dx.doi.org/10.3390/life11080838 |
work_keys_str_mv | AT chanjasonyongsheng towardsnextgenerationbiomarkersinnaturalkillertcelllymphoma AT limjingquan towardsnextgenerationbiomarkersinnaturalkillertcelllymphoma AT ongchoonkiat towardsnextgenerationbiomarkersinnaturalkillertcelllymphoma |